Back to Search
THOMAS HUTSON, DO,PHARMD
DO,PHARMD
Medical Oncology Physician
NPI: 1609819069IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
L5774(TX)
Education
OHIO UNIVERSITY, COLLEGE OF OSTEOPATHIC MEDICINE
Class of 1997
Research & Publications (20)
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
PMID 19633050·Ann Oncol·2010
3-trial
Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.
PMID 18928373·Expert Rev Anticancer Ther·2008
6-review
Experimental therapy for advanced renal cell carcinoma.
PMID 18922106·Expert Opin Investig Drugs·2008
6-review
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
PMID 18838439·Oncologist·2008
6-review
Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
PMID 17892420·Expert Rev Anticancer Ther·2007
6-review
Evolving role of novel targeted agents in renal cell carcinoma.
PMID 17926797·Oncology (Williston Park)·2007
1-meta
Targeted therapy for renal cell carcinoma: a new treatment paradigm.
PMID 17637878·Proc (Bayl Univ Med Cent)·2007
8-other
Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
PMID 17239282·Clin Genitourin Cancer·2006
6-review
A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.
PMID 16729915·Clin Genitourin Cancer·2006
8-other
Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
PMID 16425986·Clin Genitourin Cancer·2005
6-review
Renal cell carcinoma: diagnosis and treatment, 1994-2003.
PMID 16252025·Proc (Bayl Univ Med Cent)·2005
8-other
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
PMID 18236006·Invest New Drugs·2008
3-trial
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
PMID 19262991·Invest New Drugs·2010
8-other
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
PMID 19171708·J Clin Oncol·2009
3-trial
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
PMID 19403937·Ann Oncol·2009
8-other
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
PMID 19451442·J Clin Oncol·2009
3-trial
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PMID 19487381·J Clin Oncol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3410 WORTH ST
DALLAS, TX 75246 - Phone
- (214) 370-1000
Quick Facts
- NPI
- 1609819069
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 20
Are you this provider?
Claim Your Profile